Dr. Anna Vakhrusheva is a biotech entrepreneur with over 10 years of experience in vaccines and gene therapies. She led Russia’s first recombinant SARS-CoV-2 vaccine from R&D to clinical trials within two years at Betuvax JSC. Now, as co-founder and CEO of Unlimited Bio, she focuses on multi-gene AAV therapies targeting muscle loss, cognitive decline, and immune dysfunction in aging. Her leadership has been recognized with the National Award for Women in Science and the Technological Breakthrough Award at Nobel Vision. Anna is committed to advancing safe, accessible longevity technologies and bridging cutting-edge science with real-world health applications.

The Synergy Strategy: Combining Anti-Aging Interventions for Maximum Impact.

To be announced

http://unlimited.bio